PAZOPANIB IN CHEMORESISTANT PATIENTS WITH GERM CELL TUMORS (GCT): UPDATED RESULTS OF THE OPEN-LABEL, SINGLE-GROUP, PHASE 2 PAZOTEST-01 TRIAL

被引：0
|
作者：
Necchi, Andrea [1 ]
Giannaternpo, Patrizia [2 ]
Mariani, Luigi [3 ]
Nicolai, Nicola [1 ]
Fare, Elena [2 ]
Raggi, Daniele [2 ]
Piva, Luigi [1 ]
Biasoni, Davide [1 ]
Catanzaro, Mario [1 ]
Torelli, Tullio [1 ]
Stagni, Silvia [1 ]
Maffezzini, Massimo [1 ]
Togliardi, Elena [4 ]
Salvioni, Roberto [1 ]
De Braud, Filippo [2 ]
Gianni, Alessandro [2 ]
机构：
[1] Fdn Irccs Ist Nazl Tumori, Milan, Italy
[2] Fdn Irccs Ist Nazl Tumori, Dept Oncol, Milan, Italy
[3] Fdn Irccs Ist Nazl Tumori, Clin Epidemiol & Trials Org Unit, Milan, Italy
[4] Fdn Irccs Ist Nazl Tumori, Pharm Unit, Milan, Italy
来源：
ANTICANCER RESEARCH | 2014年 / 34卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
95
引用
收藏
页码：2661 / 2662
页数：2
相关论文
共 50 条
  • [1] Pazopanib in chemoresistant patients with germ cell tumors (GCT): Updated results of the open-label, single-group, phase 2 Pazotest-01 trial.
    Glennatempo, Patrizia
    Mariani, Luigi
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Maronglu, Manuals
    Plva, Luigi
    Blasonl, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo G.
    Gianni, Alessandro M.
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01).
    Necchi, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Crippa, Flavio
    Mariani, Luigi
    Salvioni, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial
    Giannatempo, Patrizia
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Crestani, Alessandro
    Togliardi, Elena
    Salvioni, Roberto
    Gianni, Alessandro M.
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.
    Necchi, Andrea
    Lo Vullo, Salvatore
    Giannatempo, Patrizia
    Raggi, Daniele
    Calareso, Giuseppina
    Togliardi, Elena
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [5] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
    Necchi, A.
    Lo Vullo, S.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Pennati, M.
    Zaffaroni, N.
    Perrone, F.
    Busico, A.
    Colecchia, M.
    Nicolai, N.
    Mariani, L.
    Salvioni, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1346 - 1351
  • [6] An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
    Necchi, Andrea
    Magazzu, Domenico
    Anichini, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Nicolai, Nicola
    Colecchia, Maurizio
    Paolini, Biagio
    Coradeschi, Elisa
    Tassi, Elena
    Grazia, Giulia
    Mortarini, Roberta
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Salvioni, Roberto
    Gianni, Alessandro M.
    Valagussa, Pinuccia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] An open-label, single-group, phase 2 study of Brentuximab Vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): results at the end of first stage (FM12GCT01)
    Necchi, A.
    Magazzu, D.
    Anichini, A.
    Raggi, D.
    Giannatempo, P.
    Colecchia, M.
    Coradeschi, E.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Salvioni, R.
    Valagussa, P.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S56 - S56
  • [8] Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    Kaufman, Howard L.
    Russell, Jeffery
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    Chin, Kevin
    Mahnke, Lisa
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Nghiem, Paul
    [J]. LANCET ONCOLOGY, 2016, 17 (10): : 1374 - 1385
  • [9] Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
    Necchi, Andrea
    Mariani, Luigi
    Zaffaroni, Nadia
    Schwartz, Lawrence H.
    Giannatempo, Patrizia
    Crippa, Flavio
    Morosi, Carlo
    Lanocita, Rodolfo
    Sava, Teodoro
    Ortega, Cinzia
    Messina, Caterina
    Sacco, Cosimo
    Pennati, Marzia
    Daidone, Maria G.
    Nicolai, Nicola
    De Braud, Filippo
    Gianni, Alessandro M.
    Salvioni, Roberto
    [J]. LANCET ONCOLOGY, 2012, 13 (08): : 810 - 816
  • [10] An open-label, single-group, multicenter phase II study of lanreotide autogel (LAN) in Japanese patients (pts) with neuroendocrine tumors (NET).
    Ito, Tetsuhide
    Hisamatsu, Seiichi
    Nakajima, Akihiro
    Shimatsu, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345